Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01283061 | Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition | PHASE1 | COMPLETED | 44 | — | — | Dec 1, 2007 | Jan 1, 2008 | Jan 26, 2011 | 1 | India |
| Arm | Type | Description |
|---|---|---|
| zafirlukast | EXPERIMENTAL | Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited |
| Accolate | ACTIVE_COMPARATOR | ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals |
| Name | Type | Description |
|---|---|---|
| Zafirlukast | DRUG | Zafirlukast tablets 20 mg |
Inclusion Criteria: 1. The subjects should be healthy human between 18 and 45 years. 2. The subjects should be screened within 21 days prior to the administration of first dose of the study drug. 3. The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter. 4. The subjects...